In the biggest biopharma deal since January, Sanofi is bolstering its rare immunology offering by acquiring Blueprint ...

BioNTech bought out its China-based biotech partner Biotheus for $800 million upfront in November. Now, the German drugmaker ...

AstraZeneca and Daiichi Sankyo’s Enhertu plus Roche’s Perjeta demonstrated the potential to shake up first-line treatment of ...

South Korean biotech Curogen plans US expansion, adds COO Arvind Sood and board members as it preps for first clinical trial ...

Self-described “blunt pharma executives,” Jake Van Naarden and David Hyman of Eli Lilly sat down Sunday with Endpoints News ...

Vera Therapeutics’ rare kidney disease candidate atacicept appears to have pulled off an unusual trick: being more effective ...

Kymera Therapeutics reports positive Phase 1 data for oral drug KT-621, targeting STAT6 as potential competitor to ...

Zetagen Therapeutics, founded 2015, private clinical-stage biopharmaceutical company develops first-of-its-kind targeted ...